---
title: "Weekly Recap | Alvotech SA +9.25%, full-year guidance reaffirmed"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296674313.md"
description: "Alvotech SA rallied 9.25% this week to close at $4.43, outpacing the S&P 500 by roughly 10.68 percentage points as the benchmark slipped 1.43%. The week played out as a sharp recovery: shares dipped to an intraweek low of $3.77 on Monday, consolidated through midweek, then surged on Thursday and Friday, touching a high of $4.595 before settling back. The stock swung 20."
datetime: "2026-08-22T06:55:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296674313.md)
  - [en](https://longbridge.com/en/news/296674313.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296674313.md)
generator: "portal-rs"
---

# Weekly Recap | Alvotech SA +9.25%, full-year guidance reaffirmed

## The Week

Alvotech SA rallied 9.25% this week to close at $4.43, outpacing the S&P 500 by roughly 10.68 percentage points as the benchmark slipped 1.43%. The week played out as a sharp recovery: shares dipped to an intraweek low of $3.77 on Monday, consolidated through midweek, then surged on Thursday and Friday, touching a high of $4.595 before settling back. The stock swung 20.92% from trough to peak, and average daily volume ran about 55% above the 60-day median, signalling a notable pickup in participation.

## Key Events

The week’s centrepiece was the release of first-half 2026 results. Product revenue came in at $211.9 million, down 31% year-on-year, as manufacturing upgrades and quality-system enhancements constrained output. The company posted a net loss for the period and missed EPS estimates by roughly $0.17. On the earnings call, however, management flagged that manufacturing is recovering and reiterated full-year guidance, which eased concerns about prolonged operational drags and fuelled Thursday’s rally.

A separate catalyst was the licensing and commercialisation agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab, covering the US and select Asian markets. The deal broadens Alvotech’s pipeline pathway and contributed to Friday’s elevated volume.

## Analyst Ratings

Six analysts cover the stock: three rate it buy, one overweight, one hold, and one underweight. No sell or no-opinion ratings are present. The consensus recommendation is buy, with a consensus target of $5.75 — implying roughly 29.8% upside from the current price. Individual target prices range from $4.00 to $9.00, a wide spread that reflects diverging views on the pace of manufacturing recovery and biosimilar pipeline execution. Alvotech’s ranking sits mid-table among 505 biotech peers.

## The Week Ahead

On the macro front, Tuesday (25 August) brings US consumer confidence and new home sales data. A softer-than-expected print could weigh on broad risk appetite. For Alvotech, the next scheduled earnings event — the Q3 2026 report — is not until 11 November (after the close), so the market will watch for any operational updates on the manufacturing ramp and the pace of product revenue recovery. The ability to deliver on the guidance reiterated this week remains the central question.

## In Short

ALVO staged a repair rally this week, driven by the market’s decision to focus on management’s upbeat second-half outlook rather than the first-half loss. The latest session’s flow data showed large-lot money as a net seller, while smaller-lot flows stayed net buyers — a tension worth watching. With the Lotus deal adding a pipeline angle, the stock’s near-term path hinges on whether manufacturing volumes actually ramp in line with guidance and whether the biosimilar portfolio continues to deliver commercial milestones.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [ALVO.US](https://longbridge.com/en/quote/ALVO.US.md)

## Related News & Research

- [Alvotech executives to speak at Morgan Stanley Global Healthcare Conference fireside chat](https://longbridge.com/en/news/297181556.md)
- [Alvotech (NASDAQ:ALVO) Releases Earnings Results, Misses Estimates By $0.17 EPS](https://longbridge.com/en/news/296400145.md)
- [Dyadic International (Nasdaq: DYAI) Advances Next-Generation Biomanufacturing with Global Health Support](https://longbridge.com/en/news/297564670.md)
- [11:00 ETCizzle Bio Highlights CIZ1B Biomarker Blood Test for Lung Cancer at Next Generation Dx Summit](https://longbridge.com/en/news/297064751.md)
- [Bioretec hosts media event highlighting 500,000 Activa bioresorbable orthopedic implants sold worldwide](https://longbridge.com/en/news/297047388.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**